A PHP Error was encountered

Severity: Warning

Message: Undefined array key "articleIDUniqueCode"

Filename: frontend/article.php

Line Number: 189

A PHP Error was encountered

Severity: 8192

Message: substr(): Passing null to parameter #1 ($string) of type string is deprecated

Filename: frontend/article.php

Line Number: 189

">

A PHP Error was encountered

Severity: Warning

Message: Undefined array key "articleIDUniqueCode"

Filename: frontend/article.php

Line Number: 190

A PHP Error was encountered

Severity: 8192

Message: substr(): Passing null to parameter #1 ($string) of type string is deprecated

Filename: frontend/article.php

Line Number: 190

">

A PHP Error was encountered

Severity: Warning

Message: Undefined array key "articleIDUniqueCode"

Filename: frontend/article.php

Line Number: 213

A PHP Error was encountered

Severity: 8192

Message: substr(): Passing null to parameter #1 ($string) of type string is deprecated

Filename: frontend/article.php

Line Number: 213

">

A PHP Error was encountered

Severity: Warning

Message: Undefined array key "articleIDUniqueCode"

Filename: frontend/article.php

Line Number: 214

A PHP Error was encountered

Severity: 8192

Message: substr(): Passing null to parameter #1 ($string) of type string is deprecated

Filename: frontend/article.php

Line Number: 214

">

View Article

Abstract

Zebrafish (Danio rerio) has emerged as a powerful and versatile model organism in pharmaceutical research due to its unique biological and genetic attributes. With approximately 70% genetic similarity to humans and functional conservation of disease-related genes, zebrafish serve as an efficient platform for studying human diseases, drug screening, and toxicity assessment. Their small size, rapid development, and high fecundity make them ideal for large-scale in vivo experiments, particularly in developmental biology, pharmacology, and toxicology. Transparency of embryos allows real-time imaging of physiological and pathological processes, enhancing their applicability in high-throughput drug screening. Zebrafish models have been instrumental in advancing our understanding of neurological disorders, cardiovascular diseases, metabolic syndromes and cancer. However, advancements in genetic engineering, imaging technologies, and automation are addressing these challenges. This review provides a comprehensive overview of zebrafish applications in pharmaceutical research, discussing their advantages, limitations, and future prospects in drug development and translational medicine.

Keywords

Zebrafish model, Research, Genetic, Pharmacology

Introduction

× Popup Image

Zebrafish (Danio rerio), a small freshwater fish native to South Asia, has gained significant attention as a powerful model organism in biomedical and pharmaceutical research. Due to its unique biological and genetic characteristics, zebrafish has become an essential tool for studying human diseases, drug screening, and toxicity assessment [1]. Compared to traditional mammalian models such as mice and rats, zebrafish offer several advantages, including their ease of maintenance, rapid development, and high-throughput screening potential. These attributes make zebrafish a cost-effective and efficient alternative for studying various aspects of human health and disease [2,3]. Their use has expanded in recent years, particularly in developmental biology, toxicology, pharmacology, and genetic research. Biologically, zebrafish possess several key characteristics that make them ideal for laboratory studies. They are small in size, measuring about 2.5–5 cm in length, and have a relatively short lifespan of around 2–3 years. Their external fertilization and transparent embryos allow for real-time observation of early developmental processes, providing a unique advantage over mammalian models, where embryonic development occurs internally. One of the most notable features of zebrafish is their rapid development, with major organ systems forming within the first 24–48 hours post-fertilization [4]. This makes them highly suitable for studying embryogenesis, organogenesis, and genetic modifications in real time. Additionally, zebrafish exhibit a high reproductive rate, with a single female capable of laying hundreds of eggs per week. This large number of offspring facilitates large-scale experiments, making zebrafish particularly useful for genetic studies and drug screening applications [5,6]. Genetically, zebrafish share remarkable similarities with humans, making them highly relevant for translational research. Approximately 70% of zebrafish genes are homologous to human genes, and about 84% of human disease-related genes have a corresponding zebrafish counterpart. This genetic conservation allows researchers to study various human diseases in zebrafish models, including neurological disorders, cardiovascular diseases, metabolic syndromes, and cancers. Moreover, zebrafish possess well-developed organ systems that closely resemble those of humans, including the nervous, cardiovascular, immune, and digestive systems. Their functional drug targets, such as ion channels, enzymes, and receptors, are also conserved, making zebrafish an effective model for pharmacological studies [7-9]. Due to these genetic and physiological similarities, zebrafish have become an invaluable tool for studying gene function, disease mechanisms, and drug responses in a whole-organism context. The zebrafish has emerged as a powerful model organism in pharmaceutical research due to its unique biological and physiological characteristics. Initially used in developmental biology, zebrafish are now widely recognized for their utility in pharmacology, toxicology, and disease modeling. Their small size, rapid life cycle, and high fecundity make them particularly attractive for large-scale studies, including high-throughput screening of pharmaceutical compounds. Additionally, their external fertilization and optical transparency during embryonic and larval stages enable real-time imaging and in vivo analysis of physiological and pathological processes. One of the most significant advantages of zebrafish in pharmaceutical research is their genetic homology with humans. Approximately 70% of zebrafish genes are shared with humans, and around 84% of human disease-related genes have counterparts in zebrafish. This genetic similarity allows researchers to develop zebrafish models for a variety of human diseases, including cancer, neurodegenerative disorders, cardiovascular conditions, and metabolic diseases. The advent of advanced genetic manipulation techniques, such as CRISPR-Cas9 genome editing and transgenic technologies, has further strengthened the role of zebrafish as a versatile model for studying gene functions and drug responses [10-13].

Reference

  1. Cong L et al. 2013 Multiplex genome engineeringusing CRISPR/Cas9, systems. Science 339, 819–823. (doi:10.1126/science.1231143)
  2. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarloJE, Church GM. 2013 RNA-guided human genomeengineering via Cas9. Science 339, 823–826. (doi:10.1126/science.1232033)
  3. Murphey RD, Zon LI. 2006 Small moleculescreening in the zebrafish. Methods 39,255–261. (doi: 10.1016/j.ymeth.2005.09.019)
  4. Howe K et al. 2013 The zebrafish referencegenome sequence and its relationship tothe human genome. Nature 496, 498–503. (doi:10.1038/nature12111)
  5. Thayumanavan G et al. 2022 Silibinin andnaringenin against bisphenol A-inducedneurotoxicity in zebrafish model-potential flavonoidmolecules for new drug design, development, andtherapy for neurological disorders. Molecules 27,2572. (doi:10.3390/molecules27082572)
  6. Raldúa D, Piña B. 2014 In vivo zebrafish assaysfor analysing drug toxicity. Expert Opin. DrugMetab. Toxicol. 10, 685–697. (doi:10.1517/17425255.2014.896339)
  7. Opri?oreanu AM, Smith HL, Krix S, Chaytow H, Carragher NO, Gillingwater TH, Becker CG, Becker T. 021 Automated in vivo drug screen in zebrafishidentifies synapse-stabilising drugs with relevanceto spinal muscular atrophy. Dis. Model Mech. 14, dmm047761. (doi:10.1242/dmm.047761
  8. White DT et al. 2016 ARQiv-HTS, a versatile whole-organism screening platform enabling in vivo drugdiscovery at high-throughput rates. Nat. Protoc. 11,2432–2453. (doi:10.1038/nprot.2016.142)
  9. Lubin A, Otterstrom J, Hoade Y, Bjedov I, Stead E,Whelan M, Gestri G, Paran Y, Payne E. 2021 Aversatile, automated and high-throughput drugscreening platform for zebrafish embryos. Biol. Open10, bio058513. (doi:10.1242/bio.058513)
  10. Chan J, Bayliss PE, Wood JM, Roberts TM. 2002Dissection of angiogenic signaling in zebrafish usinga chemical genetic approach. Cancer Cell. 1,257–267. (doi:10.1016/S1535-6108(02)00042-9)
  11. Shinya M, Koshida MS, Sawada A, Kuroiwa A, Takeda H.2001 Fgf signalling through MAPK cascade is requiredfor development of the subpallial telencephalon inzebrafish embryos. Development 128, 4153–4164. (doi:10.1242/dev.128.21.4153)
  12. Taylor KL, Grant NJ, Temperley ND, Patton EE. 2010Small molecule screening in zebrafish: an in vivoapproach to identifying new chemical tools anddrug leads. Cell Commun. Signal 8, 11. (doi:10.1186/1478-811X-8-11)
  13. MacRae CA, Peterson RT. 2015 Zebrafish as tools fordrug discovery. Nat. Rev. Drug Discov. 14, 721–731. (doi:10.1038/nrd4627)
  14. Rennekamp AJ, Peterson RT. 2015 15 years ofzebrafish chemical screening. Curr. Opin. Chem. Biol.24, 58–70. (doi: 10.1016/j.cbpa.2014.10.025)
  15. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, ImamuraY, Yamaguchi Y, Handa H 2010 Identification of aprimary target of thalidomide teratogenicity. Science327, 1345–1350. (doi:10.1126/science.1177319)
  16. Patton EE, Zon LI, Langenau DM. 2021 Zebrafishdisease models in drug discovery: from preclinicalmodelling to clinical trials. Nat. Rev. Drug Discov.20, 611–628. (doi:10.1038/s41573-021-00210-8)
  17. 1MacRae CA, Peterson RT. 2003 Zebrafish-based smallmolecule discovery. Chem. Biol. 10, 901–908. (doi: 10.1016/j.chembiol.2003.10.003)
  18. Zon LI, Peterson RT. 2005 In vivo drug discovery inthe zebrafish. Nat. Rev. Drug Discov. 4, 35–44. (doi:10.1038/nrd1606)
  19. Richter S, Schulze U, Tomançak P, Oates AC. 2017 Smallmolecule screen in embryonic zebrafish using modularvariations to target segmentation. Nat. Commun. 8,1901. (doi:10.1038/s41467-017-01469-5)
  20. Wiley DS, Redfield SE, Zon LI. 2017 Chemicalscreening in zebrafish for novel biological andtherapeutic discovery. Methods Cell Biol. 138,651–679. (doi: 10.1016/bs.mcb.2016.10.004)
  21. Swanhart LM, Cosentino CC, Diep CQ, Davidson AJ,de Caestecker M, Hukriede NA. 2011 Zebrafishkidney development: basic science to translationalresearch. Birth Defects Res. C Embryo Today 93,141–156. (doi:10.1002/bdrc.20209)
  22. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ.2001 Experimental and computational approachesto estimate solubility and permeability in drugdiscovery and development settings. Adv. DrugDeliv. Rev. 46, 3–26. (doi:10.1016/S0169-409X (00)00129-0)
  23. Lipinski CA. 2004 Lead- and drug-like compounds: the rule-of-five revolution. Drug Disc. Today 1,337–341. (doi: 10.1016/j.ddtec.2004.11.007)
  24. Long K, Kostman SJ, Christian Fernandez C, BurnettJC, Donna M, Huryn DM. 2019 Do zebrafish obeylipinski rules? ACS Med. Chem. Lett. 10, 1002–1006. (doi:10.1021/acsmedchemlett.9b00063)
  25. Kalueff AV, Stewart AM, Gerlai R. 2014 Zebrafish asan emerging model for studying complex braindisorders. Trends Pharmacol. Sci. 35, 63–75. (doi: 10.1016/j.tips.2013.12.002)
  26. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. 2005 Lifetime prevalence and age-of-onsetdistributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 593–602. (doi:10.1001/archpsyc.62.6.593)
  27. Ziv L, Muto A, Schoonheim PJ, Meijsing SH, StrasserD, Ingraham HA, Schaaf MJ, Yamamoto KR, Baier H.2013 An affective disorder in zebrafish withmutation of the glucocorticoid receptor. Mo. Psychiatry 18, 681–691. (doi:10.1038/mp.2012.64).

Photo
Gaurav Kasar
Corresponding author

Department of Pharmacology, Divine College of Pharmacy, Satana (Nashik), India

Photo
Vaibhavi Pagar
Co-author

Department of Pharmacology, Divine College of Pharmacy, Satana (Nashik), India

Photo
Dipti Chavan
Co-author

Department of Pharmacology, Divine College of Pharmacy, Satana (Nashik), India

Photo
Dr. Chandrashekhar Patil
Co-author

Department of Pharmacology, Divine College of Pharmacy, Satana (Nashik), India

Photo
Dr. Sunil Mahajan
Co-author

Department of Pharmaceutical Chemistry, Divine College of Pharmacy, Satana (Nashik), India

Vaibhavi Pagar, Gaurav Kasar*, Dipti Chavan, Dr. Chandrashekhar Patil, Dr. Sunil Mahajan, Zebrafish Model in Pharmaceutical Research: A Review, Int. J. Sci. R. Tech., 2025, 2 (5), 535-541. https://doi.org/10.5281/zenodo.15507701

More related articles
Co-Crystals in Enhancing Drug Solubility and Stabi...
Vaishnavi Adsul, Pratik Bhabad, Dr. Swapnil phade...
Advanced Strategies for Analytical Method Developm...
Amol Naragude, Rajeev Kumar Malviya...
Artificial intelligence in drug discovery and deve...
Shubham Gurule, Sakshi Bhagat , Rutuja Avhad, Sahil Gawade, Anuja...
An Artificial Intelligence in Pharmaceutical Sciences: Current Trends, Applicati...
Ruswa Urade, Bhudevi Khapne, Rupal Kalbhut, Sandip Umare, Sujata Samant...
The Transformative Drug Impact of AI in Pharmaceutical Drug Product Development...
Roshani Nikam, Shraddha Vaishnav, Jagruti Sonawane, Karuna Sonawane, Priyanka Shinde...
3D Printing Of Oral Solid Dosage Forms: A New Era In Drug Delivery...
Deep Jyoti Shah, Pratik Kumar, Tamanna Parween, Anshika Patel, Dilip Yadav, Satish Kumar, Gautam Kum...
Related Articles
A Review on Plant Growth Promoters from Pharmaceutical Waste Management...
Siddhivinayak Jadhav, Bhagyesh Janugade, Sachin Gorad, Shravani Jadhav, Amruta Jamale...
Pharmacists as Guardians of Patient Safety: A Review of Their Critical Role in M...
Arnab Roy, Sachin Kumar, Ariza Tahseen, Shweta Patel, Tarun Kumar, Vivek Kumar, Shadab Akhtar, Raja ...
Artificial Intelligence in Pharmacy: A Boon for Drug Delivery & Drug Discovery...
Sayali Gandhi , Swapnil Katkhade, Meet Shah, Nalini Javane, Kalyani Raut, Varsharani Avhad ...
Fragment-Based Drug Discovery: Opportunities and Challenges in Pharmaceutical Ch...
Mohammad Javed, Rajasmita Bhadra, Somya Saurav, Kundan Raj Jajware, Sita Kumari...
More related articles
Artificial intelligence in drug discovery and development...
Shubham Gurule, Sakshi Bhagat , Rutuja Avhad, Sahil Gawade, Anuja Darade, Pratik Bhabad...
Artificial intelligence in drug discovery and development...
Shubham Gurule, Sakshi Bhagat , Rutuja Avhad, Sahil Gawade, Anuja Darade, Pratik Bhabad...